Irinotecan Sucrosofate

Phase 3Small molecule

Irinotecan Sucrosofate is one of 99 small molecule programs targeting Pancreatic Ductal Adenocarcinoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pancreatic Ductal AdenocarcinomaRecruiting

Pancreatic CancerRecruiting

Biliary CancerActive, not recruiting

Pancreatic Ductal AdenocarcinomaPhase 3

Recruiting

Pancreatic CancerPhase 3

Recruiting

Biliary CancerPhase 2

Active, not recruiting

Competition

Competitive Landscape

335 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Irinotecan Sucrosofate

NNorthwestern University

Phase 3

1 2

Medrol

Pfizer

Preclinical

1 3

Byetta

AstraZeneca

Preclinical

1 4

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Preclinical

1 5

Xylocaine

MMEDRx USA, Inc.

Preclinical

1 6

Feraheme

AAzurity Pharmaceuticals

Preclinical

1 7

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

1 8

Active Comparator

Moderna

Preclinical

1 9

Sulfonylureas

Eli Lilly

Preclinical

1 10

Hyperpolarized 13c Pyruvate

UUniversity of Maryland, Baltimore

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 2Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06821997

Q4 2030

Phase 3Recruiting

Pancreatic Ductal Adenocarcinoma

NCT06958328

Phase 3Recruiting

Pancreatic Cancer

NCT06998940

Clinical

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma2 trials

NALIRIFOX Before Surgery for the Treatment of Borderline Resectable Pancreatic Ductal Adenocarcinoma, Nectar Trial

Recruiting·RRoswell Park Cancer Institute·Phase 2·NCT06821997·20 enrolled

A Phase III Randomized Trial of Dose Escalated Radiation in Locally Advanced Pancreas Cancer (LAPC) Patients (LAP100)

Recruiting·NNRG Oncology·Phase 3·NCT06958328·356 enrolled

Patients With Solid Tumors1 trial

Liposomal Irinotecan and Veliparib in Treating Patients With Solid Tumors

Completed·NNational Cancer Institute (NCI)·Phase 1·NCT02631733·18 enrolled

Primary Peritoneal Cancer1 trial

Irinotecan Liposome and Bevacizumab for the Treatment of Platinum Resistant, Recurrent, or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Completed·NNorthwestern University·Phase 2·NCT04753216·3 enrolled

Pancreatic Cancer1 trial

Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations

Recruiting·SSWOG Cancer Research Network·Phase 3·NCT06998940·94 enrolled

Biliary Cancer1 trial

Liposomal Irinotecan, Fluorouracil, Leucovorin Calcium, and Rucaparib in Treating Patients With Metastatic Pancreatic, Colorectal, Gastroesophageal, or Biliary Cancer

Active, not recruiting·—·Phase 1/2·NCT03337087·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 6 trial records for Irinotecan Sucrosofate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Irinotecan Sucrosofate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Irinotecan Sucrosofate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Northwestern University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: NNorthwestern University

Irinotecan Sucrosofate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2030

Trials by Indication[1]

Pancreatic Ductal Adenocarcinoma2 trials

Patients With Solid Tumors1 trial

Primary Peritoneal Cancer1 trial

Pancreatic Cancer1 trial

Biliary Cancer1 trial

References

Drug Info

Quick Facts

Related News